S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
CarMax Slides On Earnings Disappointment, Time To Celebrate?
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Will the Energy Sector Continue to Outshine the Market?
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
CarMax Slides On Earnings Disappointment, Time To Celebrate?
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Will the Energy Sector Continue to Outshine the Market?
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
CarMax Slides On Earnings Disappointment, Time To Celebrate?
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Will the Energy Sector Continue to Outshine the Market?
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
CarMax Slides On Earnings Disappointment, Time To Celebrate?
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Will the Energy Sector Continue to Outshine the Market?
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
NASDAQ:PEAR

Pear Therapeutics (PEAR) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
15 shs
Average Volume
7.75 million shs
Market Capitalization
$4.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Pear Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
∞ Upside
$6.67 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Pear Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.85) to ($0.50) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

See Top Rated MarketRank™ Stocks Here

PEAR stock logo

About Pear Therapeutics (NASDAQ:PEAR) Stock

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.


PEAR Stock News Headlines

September 28, 2023 | benzinga.com
Migraine Pipeline, Clinical Trials, Emerging Therapies and FDA Approvals 2023 (Updated)
September 25, 2023 | finance.yahoo.com
Pear Therapeutics, Inc. (PEARQ)
September 30, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
September 14, 2023 | axios.com
ADHD video game maker Akili shifts focus from prescription to OTC, lays off 40%
September 13, 2023 | bizjournals.com
Digital health startup Akili cuts staff by 40%, abandons prescription model
August 28, 2023 | benzinga.com
Shaping the Future of Medicine: Anticipated $17.7 Billion Digital Therapeutics Market by 2027
August 23, 2023 | msn.com
Former execs from defunct Pear Therapeutics start VC firm
July 27, 2023 | msn.com
Startups Struggle With Insurers Over Digital Treatments
September 30, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
July 3, 2023 | bizjournals.com
Biotech layoffs 2023: In Q2, more than 700 Boston-area life science jobs were cut
June 26, 2023 | forbes.com
Prescription Digital Therapeutics For Mental Health: What It Means For Doctors And Their Patients
June 22, 2023 | marketwatch.com
Digital Therapeutics (DTx) Market Research Report 2023 Future Opportunities, Latest Trends, In-depth Analysis, and Forecast To 2030
June 20, 2023 | finance.yahoo.com
Nox Health Closes Acquisition of Somryst, the Only FDA-Cleared Digital Insomnia Treatment, From Pear Therapeutics
June 12, 2023 | bizjournals.com
BehaVR adds 3 executives to senior leadership team
June 8, 2023 | finance.yahoo.com
Global Digital Therapeutics [DTx] for Mental Health Market Size
June 8, 2023 | finance.yahoo.com
BehaVR Appoints Former Pear Therapeutics, TytoCare and AVIA Executives to Senior Leadership Team
May 22, 2023 | axios.com
Pear Therapeutics sold for parts
May 16, 2023 | marketwatch.com
Digital Therapeutics Market 2023 Industry Trends, Growth, Size, Segmentation, Opportunities and Revenue by Forecast to 2031
May 14, 2023 | markets.businessinsider.com
Chardan Capital Reaffirms Their Buy Rating on Orchestra BioMed Holdings (OBIO)
May 9, 2023 | markets.businessinsider.com
Seres Therapeutics (MCRB) Gets a Buy from Chardan Capital
May 9, 2023 | investing.com
Pear Therapeutics Inc (PEARQ)
May 5, 2023 | markets.businessinsider.com
Chardan Capital Remains a Buy on Omega Therapeutics (OMGA)
May 4, 2023 | markets.businessinsider.com
Chardan Capital Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
May 3, 2023 | wsj.com
Firm Retention Summary: Pear Therapeutics
April 29, 2023 | marketwatch.com
Digital Therapeutics (DTx) Market Growth Strategies, Size, Geography Trends and Competitive Analysis to 2030
April 17, 2023 | finance.yahoo.com
It's Down 82% But Pear Therapeutics, Inc. (NASDAQ:PEAR) Could Be Riskier Than It Looks
April 14, 2023 | msn.com
Why Navidea Biopharmaceuticals Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
See More Headlines
Receive PEAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pear Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PEAR Company Calendar

Today
9/30/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Health services
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PEAR
CUSIP
N/A
CIK
1835567
Web
peartherapeutics.com
Phone
617-925-7848
Fax
N/A
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.67
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$5.00
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.22)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-75,490,000.00
Net Margins
-594.70%
Pretax Margin
-594.70%
Return on Equity
-217.85%
Return on Assets
-95.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.48
Quick Ratio
1.48

Sales & Book Value

Annual Sales
$12.69 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.22 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
142,739,000
Free Float
98,918,000
Market Cap
$4.17 million
Optionable
Not Optionable
Beta
0.45
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Corey M. McCann M.D. (Age 43)
    Ph.D., Founder, Pres, CEO & Director
    Comp: $702.45k
  • Mr. Christopher D. T. Guiffre J.D. (Age 55)
    M.B.A., MBA, CFO, COO, Treasurer & Assistant Sec.
    Comp: $564.37k
  • Ms. Julia M. Strandberg M.B.A. (Age 48)
    Chief Commercial Officer
    Comp: $582.43k
  • Mr. Ronan P. O'Brien J.D. (Age 50)
    Chief Compliance Officer, Gen. Counsel & Sec.
  • Ms. Meara Murphy
    Sr. Director of Corp. Communications
  • Dr. Yuri Maricich M.B.A. (Age 43)
    M.D., Chief Medical Officer & Head of Devel.
  • Mr. Chris Valosky M.B.A.
    VP of Sales
  • Ms. Katherine Jeffery M.Sc. (Age 56)
    Chief People Officer
  • Ms. Erin K. Brenner (Age 50)
    Chief Product Devel. Officer
  • Ms. Ellen E. Snow CPA (Age 50)
    CGMA, VP & Corp. Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PEAR Stock - Frequently Asked Questions

Should I buy or sell Pear Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pear Therapeutics in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PEAR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PEAR, but not buy additional shares or sell existing shares.
View PEAR analyst ratings or view top-rated stocks.

What is Pear Therapeutics' stock price forecast for 2023?

4 Wall Street research analysts have issued 12-month target prices for Pear Therapeutics' stock. Their PEAR share price forecasts range from $5.00 to $8.00. On average, they expect the company's share price to reach $6.67 in the next year.
View analysts price targets for PEAR or view top-rated stocks among Wall Street analysts.

What is Pear Therapeutics' stock symbol?

Pear Therapeutics trades on the NASDAQ under the ticker symbol "PEAR."

How do I buy shares of Pear Therapeutics?

Shares of PEAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Pear Therapeutics make?

Pear Therapeutics (NASDAQ:PEAR) has a market capitalization of $0.00 and generates $12.69 million in revenue each year. The company earns $-75,490,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does Pear Therapeutics have?

The company employs 300 workers across the globe.

How can I contact Pear Therapeutics?

Pear Therapeutics' mailing address is 195 CHURCH STREET 15TH FLOOR, NEW HAVEN CT, 06510. The official website for the company is peartherapeutics.com. The company can be reached via phone at 617-925-7848 or via email at meara.murphy@peartherapeutics.com.

This page (NASDAQ:PEAR) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -